Tolcapone | CAS#134308-13-7

Tolcapone
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318886

CAS#: 134308-13-7

Description: Tolcapone is a drug used to treat Parkinson's disease (PD). It is a selective, potent and reversible nitro catechol type inhibitor of enzyme catechol-O-methyl transferase (COMT).

Chemical Structure

Tolcapone

CAS# 134308-13-7

Instruction

Theoretical Analysis

MedKoo Cat#: 318886
Name: Tolcapone
CAS#: 134308-13-7
Chemical Formula: C14H11NO5
Exact Mass: 273.06
Molecular Weight: 273.241
Elemental Analysis: C, 61.54; H, 4.06; N, 5.13; O, 29.28

Price and Availability

Size	Price	Availability	Quantity
50mg	USD 450
100mg	USD 750
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Tolcapone, Tasmar, Ro 40-7592, SOM0226

IUPAC/Chemical Name: (3,4-dihydroxy-5-nitrophenyl)-(4-methylphenyl)methanone

InChi Key: MIQPIUSUKVNLNT-UHFFFAOYSA-N

InChi Code: InChI=1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3

SMILES Code: O=C(C1=CC([N+]([O-])=O)=C(O)C(O)=C1)C2=CC=C(C)C=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 273.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Truong DD. Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease. Clin Interv Aging. 2009;4:109-13. Epub 2009 May 14. Review. PubMed PMID: 19503773; PubMed Central PMCID: PMC2685232.

2: Pilipovich AA, Golubev VL. [Tolcapone in the management of Parkinson's disease]. Zh Nevrol Psikhiatr Im S S Korsakova. 2007;107(6):71-8. Review. Russian. PubMed PMID: 18688929.

3: Leegwater-Kim J, Waters C. Role of tolcapone in the treatment of Parkinson's disease. Expert Rev Neurother. 2007 Dec;7(12):1649-57. Review. PubMed PMID: 18052761.

4: Olanow CW, Watkins PB. Tolcapone: an efficacy and safety review (2007). Clin Neuropharmacol. 2007 Sep-Oct;30(5):287-94. Review. PubMed PMID: 17909307.

5: Konopka M, Członkowski A. [Comparison of the safety of the medicinal product in the European Union and the United States, tolcapone (Tasmar) -- COMT inhibitor as the analyzed example]. Neurol Neurochir Pol. 2005 Nov-Dec;39(6):490-6. Review. Polish. PubMed PMID: 16355307.

6: Borges N. Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy. Drug Saf. 2003;26(11):743-7. Review. PubMed PMID: 12908845.

7: Borroni E, Cesura AM, Gatti S, Gasser R. A preclinical re-evaluation of the safety profile of tolcapone. Funct Neurol. 2001;16(4 Suppl):125-34. Review. PubMed PMID: 11996507.

8: Colosimo C. The rise and fall of tolcapone. J Neurol. 1999 Oct;246(10):880-2. Review. PubMed PMID: 10552233.

9: Jorga KM. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers. Neurology. 1998 May;50(5 Suppl 5):S31-8. Review. PubMed PMID: 9591520.

10: Lees AJ. Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease. CNS Neurosci Ther. 2008 Spring;14(1):83-93. doi: 10.1111/j.1527-3458.2007.00035.x. Review. PubMed PMID: 18482101.

11: Stocchi F, De Pandis MF. Utility of tolcapone in fluctuating Parkinson's disease. Clin Interv Aging. 2006;1(4):317-25. Review. PubMed PMID: 18046910; PubMed Central PMCID: PMC2699640.

12: Leegwater-Kim J, Waters C. Tolcapone in the management of Parkinson's disease. Expert Opin Pharmacother. 2006 Nov;7(16):2263-70. Review. PubMed PMID: 17059382.

13: Borges N. Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy. Expert Opin Drug Saf. 2005 Jan;4(1):69-73. Review. PubMed PMID: 15709899.

14: Keating GM, Lyseng-Williamson KA. Tolcapone: a review of its use in the management of Parkinson's disease. CNS Drugs. 2005;19(2):165-84. Review. PubMed PMID: 15697329.

15: Micek ST, Ernst ME. Tolcapone: a novel approach to Parkinson's disease. Am J Health Syst Pharm. 1999 Nov 1;56(21):2195-205. Review. PubMed PMID: 10565698.

16: Guay DR. Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease. Pharmacotherapy. 1999 Jan;19(1):6-20. Review. PubMed PMID: 9917075.

17: Avila A, Kulisevsky J. [Treatment of Parkinson's disease with COMT inhibitors: tolcapone]. Neurologia. 1998;13 Suppl 1:66-71. Review. Spanish. PubMed PMID: 9859687.

Your view history

Tolcapone featured